Abstract

A systematic review of the patient burden of Crohn's disease-related rectovaginal and anovaginal fistulas

BMC Gastroenterol. 2022 Jan 28;22(1):36. doi: 10.1186/s12876-021-02079-8.

Kristy Iglay 1, Dimitri Bennett 2 3, Michael D Kappelman 4, Sydney Thai 5 6, Molly Aldridge 5, Chitra Karki 2, Suzanne F Cook 5

 
     

Author information

  • 1CERobs Consultancy LLC, Wrightsville Beach, NC, 27480, USA. kristy.iglay@laylen.com.
  • 2Takeda Pharmaceuticals, Cambridge, MA, 02139, USA.
  • 3Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • 4Chapel Hill School of Medicine, Pediatric Gastroenterology, University of North Carolina, Chapel Hill, NC, 27599, USA.
  • 5CERobs Consultancy LLC, Wrightsville Beach, NC, 27480, USA.
  • 6Gillings School of Public Health, Epidemiology, University of North Carolina-Chapel Hill, Chapel Hill, NC, 27599, USA.

Abstract

Background: Crohn's disease (CD)-related rectovaginal fistulas (RVFs) and anovaginal fistulas (AVFs) are rare, debilitating conditions that present a substantial disease and treatment burden for women. This systematic literature review (SLR) assessed the burden of Crohn's-related RVF and AVF, summarizing evidence from observational studies and highlighting knowledge gaps.

Methods: This SLR identified articles in PubMed and Embase that provide data and insight into the patient experience and disease burden of Crohn's-related RVF and AVF. Two trained reviewers used pre-specified eligibility criteria to identify studies for inclusion and evaluate risk of bias using the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool for observational studies.

Results: Of the 582 records identified, 316 full-text articles were assessed, and 16 studies met a priori eligibility criteria and were included. Few epidemiology studies were identified, with one study estimating the prevalence of RVF to be 2.3% in females with Crohn's disease. Seven of 12 treatment pattern studies reported that patients had or required additional procedures before and/or after the intervention of interest, demonstrating a substantial treatment burden. Seven of 11 studies assessing clinical outcomes reported fistula healing rates between 50 and 75%, with varying estimates based on population and intervention.

Conclusions: This SLR reports the high disease and treatment burden of Crohn's-related RVF and AVF and identifies multiple evidence gaps in this field. The literature lacks robust, generalizable data, and demonstrates a compelling need for substantial, novel research into these rare and debilitating sequelae of CD. Registration The PROSPERO registration number for the protocol for this systematic literature review is CRD42020177732.

 

 

© Copyright 2013-2022 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.